Megan Moriarty
Psychiatric/Mental Health · Lafayette, INNPI 1285306332
Payments from drug & device makers
Across 169 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$522
- Vanda Pharmaceuticals Inc.$392
- AbbVie$328
- Johnson & Johnson$271
- Lundbeck LLC$247
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$226
- plus $969 from 11 others
What the payments were for
- Food & beverage$2,955100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 36 | $522 |
| Vanda Pharmaceuticals Inc. | 16 | $392 |
| AbbVie | 18 | $328 |
| Johnson & Johnson | 23 | $271 |
| Lundbeck LLC | 15 | $247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $226 |
| Axsome Therapeutics, Inc. | 7 | $162 |
| E.r. Squibb & Sons, L.L.C. | 9 | $154 |
| Alkermes, Inc. | 7 | $134 |
| Teva Pharmaceuticals USA, Inc. | 6 | $133 |
| Neurocrine Biosciences, Inc. | 6 | $123 |
| Corium, LLC | 5 | $91 |
| Ironshore Pharmaceuticals Inc. | 3 | $60 |
| Indivior Inc. | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$2,955 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 72 | $118,761 |
| Invega SustennaPaliperidone Palmitate | 44 | $106,802 |
| Austedo XrDeutetrabenazine | 23 | $85,809 |
| Abilify MaintenaAripiprazole | 32 | $77,830 |
| VraylarCariprazine Hcl | 53 | $75,784 |
| RexultiBrexpiprazole | 33 | $37,681 |
| Risperdal ConstaRisperidone Microspheres | 22 | $13,815 |
| BelsomraSuvorexant | 23 | $10,248 |
| Aripiprazole | 59 | $9,975 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,395 |
| QuviviqDaridorexant Hcl | 11 | $5,605 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 151 | $4,685 |
| QelbreeViloxazine Hcl | 12 | $4,182 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 45 | $3,283 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $3,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $271 | $120,61766 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $226 | $118,76172 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $522 | $115,51165 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $133 | $85,80923 claims |
| AbbVieVraylar | $328 | $75,78453 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $5,60511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Lafayette
- Christy McLaughlinLafayette$9K
- Hayley KaelinLafayette$8K
- Leann SharpLafayette$7K
- Bimala DevkotaLafayette$6K
- Diana KingLafayette$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.